The serotonin syndrome. Implicated drugs, pathophysiology and management
- PMID: 7576268
- DOI: 10.2165/00002018-199513020-00004
The serotonin syndrome. Implicated drugs, pathophysiology and management
Abstract
The serotonin syndrome has increasingly been recognised in patients who have received combined serotonergic drugs. This syndrome is characterised by a constellation of symptoms (confusion, fever, shivering, diaphoresis, ataxia, hyperelflexia, myoclonus or diarrhoea) in the setting of the recent addition of a serotonergic agent. The most common drug combinations causing the serotonin syndrome are monoamine oxidase inhibitors (MAOIs) and serotonin selective reuptake inhibitors (SSRIs), MAOIs and tricyclic antidepressants, MAOIs and tryptophan, and MAOIs and pethidine (meperidine). This syndrome is caused by excess serotonin (5-hydroxytryptamine; 5-HT) availability in the CNS at the 5-HT1A-receptor. There may also be some interaction with dopamine and 5-HT2-receptors. This syndrome probably has a low incidence, even among patients taking these drug combinations, and there is likely to be some other as yet unidentified inciting factor causing some patients to develop a full serotonin syndrome. Because fatalities and severe complications have accompanied the serotonin syndrome, the previously described drug combinations should be used cautiously or not at all. The serotonin syndrome is usually mild and, if managed with drug withdrawal and supportive therapy, generally improves within hours. Patients who develop hyperthermia should be treated aggressively with external cooling and paralysis. Methysergide and cyproheptadine appear to be useful adjuncts in treating the serotonin syndrome.
Similar articles
-
Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.J Clin Psychopharmacol. 1997 Jun;17(3):208-21. doi: 10.1097/00004714-199706000-00012. J Clin Psychopharmacol. 1997. PMID: 9169967 Review.
-
[The serotonin syndrome: review of the literature and description of an original study].Encephale. 1995 Sep-Oct;21(5):537-43. Encephale. 1995. PMID: 8529562 Review. French.
-
Serotonin toxicity of serotonergic psychedelics.Psychopharmacology (Berl). 2022 Jun;239(6):1881-1891. doi: 10.1007/s00213-021-05876-x. Epub 2021 Jul 12. Psychopharmacology (Berl). 2022. PMID: 34251464 Review.
-
[Serotonin syndrome and pain medication : What is relevant for practice?].Schmerz. 2015 Apr;29(2):229-51. doi: 10.1007/s00482-015-1512-0. Schmerz. 2015. PMID: 25860200 Review. German.
-
Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.Clin Ther. 2016 Jun;38(6):1498-1509. doi: 10.1016/j.clinthera.2016.04.004. Epub 2016 May 17. Clin Ther. 2016. PMID: 27206567 Clinical Trial.
Cited by
-
Clinically significant drug interactions with agents specific for migraine attacks.CNS Drugs. 2001;15(2):105-18. doi: 10.2165/00023210-200115020-00003. CNS Drugs. 2001. PMID: 11460889 Review.
-
Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment.Curr Pain Headache Rep. 2016 Aug;20(8):50. doi: 10.1007/s11916-016-0579-3. Curr Pain Headache Rep. 2016. PMID: 27457368 Review.
-
The serotonin syndrome-the need for physician's awareness.Int J Emerg Med. 2010 Aug 20;3(4):373-7. doi: 10.1007/s12245-010-0195-7. Int J Emerg Med. 2010. PMID: 21373307 Free PMC article.
-
Serotonin syndrome and drug combinations: focus on MAOI and RIMA.Eur Arch Psychiatry Clin Neurosci. 1997;247(3):113-9. doi: 10.1007/BF03033064. Eur Arch Psychiatry Clin Neurosci. 1997. PMID: 9224903 Review.
-
Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system.Drug Saf. 1999 Mar;20(3):277-87. doi: 10.2165/00002018-199920030-00007. Drug Saf. 1999. PMID: 10221856
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources